BBIO

BridgeBio Pharma, Inc.

Phase 2 AI-extracted

acoramidis

transthyretin amyloid cardiomyopathy (ATTR-CM)

Resolved

64days ago

Phase 2 readout · May 4, 2026

What's at stake Phase 2 trial results for acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) are due May 4, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 16h ago

“On May 4, 2026, the Brazilian Health Regulatory Agency (ANVISA) approved BEYONTTRA™ (acoramidis) for use in adult patients with ATTR-CM in Brazil.”

Add to calendar Post on X Reddit

Provenance